Clinical Trials Logo

Neoplasms clinical trials

View clinical trials related to Neoplasms.

Filter by:

NCT ID: NCT00389584 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Irinotecan and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Solid Tumors

Start date: December 2002
Phase: Phase 1/Phase 2
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Irinotecan may make tumor cells more sensitive to radiation therapy. Giving irinotecan together with whole-brain radiation therapy may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of irinotecan when given together with whole-brain radiation therapy and to see how well they work in treating patients with brain metastases from solid tumors. (The study of side effects and best dose has ended as of 4/15/05)

NCT ID: NCT00389389 Completed - Neoplasms Clinical Trials

Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors

Start date: September 2006
Phase: Phase 1
Study type: Interventional

The primary purpose of this study is to find out what the maximum tolerated dose is for an experimental drug called AZD4877 based on the side effects experiences by patients that receive AZD4877 on a weekly basis

NCT ID: NCT00388427 Completed - Clinical trials for Malignant Solid Tumour

Safety Study Of Cetuximab Plus Dasatinib (BMS-354825) in Treating Advanced Solid Malignancies

Start date: June 2007
Phase: Phase 1
Study type: Interventional

This is an open-label, safety study of cetuximab and differing dose levels of dasatinib in adult patients with advanced solid malignancies. Cetuximab will be administered as an intravenous infusion weekly. Dasatinib will be taken orally, once a day, on a continuous schedule at differing dose levels. The primary objective of this study is to determine the toxicities and the maximum tolerated doses of dasatinib when combined with cetuximab for the treatment of advanced solid tumors.

NCT ID: NCT00388336 Completed - Neoplasms Clinical Trials

PROCRIT (Epoetin Alfa) 60,000 Units Administered Once Every Two Weeks in Anemic Cancer Patients Who Are Not Receiving Chemotherapy or Radiation Therapy

Start date: February 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effectiveness and safety of Epoetin alfa administered at 60,000 Units every two weeks in cancer patients who are not receiving chemotherapy or radiation therapy.

NCT ID: NCT00387920 Completed - Clinical trials for Unspecified Childhood Solid Tumor, Protocol Specific

Sunitinib in Treating Young Patients With Refractory Solid Tumors

Start date: October 2006
Phase: Phase 1
Study type: Interventional

This phase I trial is studying the side effects and best dose of sunitinib in treating young patients with refractory solid tumors. Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for their growth and by blocking blood flow to the tumor.

NCT ID: NCT00387504 Completed - Clinical trials for Unspecified Adult Solid Tumor, Protocol Specific

Fenretinide in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors

Start date: November 2006
Phase: Phase 1
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as fenretinide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I trial is studying the side effects and best dose of fenretinide in treating patients with metastatic or unresectable malignant solid tumors.

NCT ID: NCT00386451 Completed - Neoplasms Clinical Trials

Comparing a Closing System Without a Needle With Positive Pressure to a Heparin Lock With Positive Pressure

Start date: November 2006
Phase: N/A
Study type: Interventional

A prospective randomized study to compare 2 groups: - heparine lock with positive pressure - lock without a needle with positive pressure

NCT ID: NCT00385177 Completed - Breast Neoplasms Clinical Trials

Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors

Start date: September 2006
Phase: Phase 1
Study type: Interventional

This is a Phase 1 open-label study of SN2310 Injectable Emulsion in patients with advanced solid malignancies. The study is designed to determine the maximum tolerated dose and dose-limiting toxicity of SN2310 Injectable Emulsion, and to characterize the pharmacokinetics of SN2310 and SN-38 following intravenous administration of SN2310 Injectable Emulsion. Additionally, evaluation of side effects as a function of dose, and observation of any anti-tumor effects of SN2310 Injectable Emulsion will be made.

NCT ID: NCT00382759 Completed - Clinical trials for Hematological Malignancies

Nonmyeloablative Stem Cell Transplant in Elderly

Start date: March 2000
Phase: Phase 2/Phase 3
Study type: Interventional

The study aimed to evaluate the efficacy of a nonmyeloablative conditioning consisting of fludarabine and total body irradiation in patients older than 60 years of age

NCT ID: NCT00378482 Completed - Melanoma Clinical Trials

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

Start date: March 5, 2007
Phase: Phase 2
Study type: Interventional

This study is intended to provide access to tremelimumab for patients who have previously received tremelimumab in a clinical trial.